Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACHV NASDAQ:GERN NASDAQ:LXRX NASDAQ:SABS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHVAchieve Life Sciences$5.52$4.61$2.00▼$6.16$566.68M2.271.31 million shs1.17 million shsGERNGeron$1.15+0.9%$1.43$1.04▼$2.01$731.33M0.611.18 million shs8.11 million shsLXRXLexicon Pharmaceuticals$1.92+1.6%$1.91$0.64▼$2.53$839.53M1.071.84 million shs2.99 million shsSABSSAB Biotherapeutics$3.33-1.5%$3.70$1.60▼$6.60$258.45M0.54385,601 shs355,795 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHVAchieve Life Sciences-4.00%+4.35%-7.85%+32.37%+54.62%GERNGeron+3.18%-6.20%-18.93%-28.16%-26.30%LXRXLexicon Pharmaceuticals+0.53%-0.53%-21.58%+11.83%+169.19%SABSSAB Biotherapeutics+2.11%-2.59%-6.63%-18.55%+79.79%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHVAchieve Life Sciences$5.52$4.61$2.00▼$6.16$566.68M2.271.31 million shs1.17 million shsGERNGeron$1.15+0.9%$1.43$1.04▼$2.01$731.33M0.611.18 million shs8.11 million shsLXRXLexicon Pharmaceuticals$1.92+1.6%$1.91$0.64▼$2.53$839.53M1.071.84 million shs2.99 million shsSABSSAB Biotherapeutics$3.33-1.5%$3.70$1.60▼$6.60$258.45M0.54385,601 shs355,795 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHVAchieve Life Sciences-4.00%+4.35%-7.85%+32.37%+54.62%GERNGeron+3.18%-6.20%-18.93%-28.16%-26.30%LXRXLexicon Pharmaceuticals+0.53%-0.53%-21.58%+11.83%+169.19%SABSSAB Biotherapeutics+2.11%-2.59%-6.63%-18.55%+79.79%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACHVAchieve Life Sciences 3.00Buy$14.67165.70% UpsideGERNGeron 2.00Hold$2.50117.39% UpsideLXRXLexicon Pharmaceuticals 2.33Hold$4.55136.98% UpsideSABSSAB Biotherapeutics 2.80Moderate Buy$11.00230.33% UpsideCurrent Analyst Ratings BreakdownLatest SABS, LXRX, GERN, and ACHV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/26/2026GERNGeron Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/22/2026ACHVAchieve Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/22/2026SABSSAB Biotherapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$11.005/20/2026SABSSAB Biotherapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$11.005/20/2026SABSSAB Biotherapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$11.005/12/2026SABSSAB Biotherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.00 ➝ $10.005/11/2026LXRXLexicon Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$2.30 ➝ $3.105/11/2026SABSSAB Biotherapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/11/2026SABSSAB Biotherapeutics Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.005/8/2026ACHVAchieve Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/27/2026GERNGeron Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACHVAchieve Life SciencesN/AN/AN/AN/A$0.40 per shareN/AGERNGeron$183.88M4.01N/AN/A$0.35 per share3.29LXRXLexicon Pharmaceuticals$49.80M17.13N/AN/A$0.30 per share6.40SABSSAB Biotherapeutics$1.32M192.89$0.34 per share9.89$3.18 per share1.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACHVAchieve Life Sciences-$54.65M-$1.12N/AN/AN/AN/A-193.49%-111.88%8/6/2026 (Estimated)GERNGeron-$83.50M-$0.11N/A11.50N/A-35.48%-23.31%-10.08%8/5/2026 (Estimated)LXRXLexicon Pharmaceuticals-$50.34M-$0.07N/AN/AN/A-37.46%-18.64%-11.79%8/5/2026 (Estimated)SABSSAB Biotherapeutics$13.27M-$2.11N/AN/AN/AN/A-0.29%-0.25%8/6/2026 (Estimated)Latest SABS, LXRX, GERN, and ACHV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026ACHVAchieve Life Sciences-$0.30-$0.19+$0.11-$0.19N/AN/A5/12/2026Q1 2026SABSSAB Biotherapeutics-$0.20-$0.35-$0.15-$0.35$0.13 millionN/A5/7/2026Q1 2026LXRXLexicon Pharmaceuticals-$0.04-$0.0026+$0.0374N/A$9.79 million$21.10 million5/6/2026Q1 2026GERNGeron-$0.03-$0.01+$0.02-$0.01$50.59 million$51.84 million3/24/2026Q4 2025ACHVAchieve Life Sciences-$0.27-$0.28-$0.01-$0.28N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACHVAchieve Life SciencesN/AN/AN/AN/AN/AGERNGeronN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/ASABSSAB BiotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACHVAchieve Life Sciences0.872.622.62GERNGeron0.526.784.96LXRXLexicon Pharmaceuticals0.2418.8018.77SABSSAB Biotherapeutics0.0111.4511.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACHVAchieve Life Sciences33.52%GERNGeron73.71%LXRXLexicon Pharmaceuticals74.70%SABSSAB Biotherapeutics7.82%Insider OwnershipCompanyInsider OwnershipACHVAchieve Life Sciences3.00%GERNGeron1.71%LXRXLexicon Pharmaceuticals14.00%SABSSAB Biotherapeutics25.06%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACHVAchieve Life Sciences20102.66 million99.58 millionOptionableGERNGeron70641.52 million630.55 millionOptionableLXRXLexicon Pharmaceuticals140444.20 million382.01 millionOptionableSABSSAB Biotherapeutics14076.46 million57.30 millionNot OptionableSABS, LXRX, GERN, and ACHV HeadlinesRecent News About These CompaniesSAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual MeetingMay 29, 2026 | finance.yahoo.comSAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual MeetingMay 29, 2026 | globenewswire.comCitigroup initiates coverage of SAB Biotherapeutics (SABS) with buy recommendationMay 23, 2026 | msn.comWhy SAB Biotherapeutics, Inc.’s (SABS) Stock Is Up 7.01%May 21, 2026 | aaii.comASAB Biotherapeutics Inc SABSMay 20, 2026 | morningstar.comMJefferies initiates coverage of SAB Biotherapeutics (SABS) with buy recommendationMay 20, 2026 | msn.comSAB Biotherapeutics Signs Manufacturing Pact for SAB-142May 16, 2026 | theglobeandmail.comWe Think SAB Biotherapeutics (NASDAQ:SABS) Needs To Drive Business Growth CarefullyMay 16, 2026 | finance.yahoo.comSAB Biotherapeutics Inc (SABS) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Rising ...May 12, 2026 | finance.yahoo.comSAB BIO Reports Q1 2026 Financial Results and Recent Business HighlightsMay 12, 2026 | globenewswire.comSAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ETMay 5, 2026 | globenewswire.comEmergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB ...April 29, 2026 | caledonianrecord.comCSAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026April 22, 2026 | globenewswire.comSAB Biotherapeutics Looks Undervalued If SAB-142 Delivers In Type 1 DiabetesApril 15, 2026 | seekingalpha.comSAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society CongressApril 15, 2026 | markets.businessinsider.comSAB Biotherapeutics closes $85 million public offeringMarch 20, 2026 | thepharmaletter.comTSAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded WarrantsMarch 19, 2026 | globenewswire.comSAB Biotherapeutics Launches Major Equity Financing OfferingMarch 19, 2026 | tipranks.comSAB Biotherapeutics, Inc. Prices Public Offering of Common Stock and Pre-Funded Warrants to Raise Approximately $85 MillionMarch 17, 2026 | quiverquant.comQSAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded WarrantsMarch 17, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSABS, LXRX, GERN, and ACHV Company DescriptionsAchieve Life Sciences NASDAQ:ACHV$5.52 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$5.62 +0.11 (+1.90%) As of 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.Geron NASDAQ:GERN$1.15 +0.01 (+0.88%) Closing price 04:00 PM EasternExtended Trading$1.16 +0.01 (+0.43%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Lexicon Pharmaceuticals NASDAQ:LXRX$1.92 +0.03 (+1.59%) Closing price 04:00 PM EasternExtended Trading$1.94 +0.02 (+0.78%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.SAB Biotherapeutics NASDAQ:SABS$3.33 -0.05 (-1.48%) Closing price 04:00 PM EasternExtended Trading$3.52 +0.19 (+5.56%) As of 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
